NVO - Novo Nordisk A/S So'nggi Yangiliklar | Finranks

27.03.2026

Novo Nordisk: A Strong Contender in the Pharmaceutical Arena

Explore the exciting world of Novo Nordisk (NVO 1.07%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

27.03.2026

Novo Nordisk's Awiqli Gets FDA Approval for Type II Diabetes

NVO secures FDA nod for Awiqli, a once-weekly basal insulin for type II diabetes, strengthening its portfolio and showing strong efficacy in studies.

27.03.2026

Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy?

One of these companies' lineup and pipeline within weight management and outside look much stronger. Valuation does not tip the scale in the other's favor.

27.03.2026

Novo Nordisk: A Comeback Story In The World's Fastest-Growing Drug Market

Novo Nordisk is positioned as a durable No. 2 in the obesity drug market, not a loser to Eli Lilly. NVO is expanding manufacturing, advancing next-generation therapies like CagriSema, and leveraging price leadership and direct-to-consumer channels. With a forward P/E of 11–15x, NVO trades at a deep discount to peers and historical averages, despite strong fundamentals and growth prospects.

27.03.2026

Articles of Association for Novo Nordisk A/S 2026

500 - Internal server error. Server Error 500 - Internal server error.

26.03.2026

US FDA approves Novo's insulin injection for type 2 diabetes

The U.S. Food and ‌Drug Administration (FDA) has approved Novo Nordisk 's ⁠insulin injection, Awiqli, to improve blood sugar levels in adults living ‌with ⁠type 2 diabetes, the company ⁠said on Thursday.

26.03.2026

Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes

FDA has approved Awiqli® injection 700 units/mL, the first and only once-weekly, long-acting basal insulin as an adjunct to diet and exercise to improve ..

Videolar

20.03.2026

Neutral

India's weight-loss drug boom: Novo Nordisk talks about GLP-1 generics after patent expiry

09.03.2026

Positive

HIMS Skyrockets on Reported Deal with NVO to Sell GLP-1s

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
NVO	TD Cowen	Hold	undefined >> $42	March 10th 2026
NVO	Morgan Stanley	Equal Weight	undefined >> $40	March 3rd 2026
NVO	Goldman	Neutral	undefined >> $41	March 2nd 2026
NVO	JP Morgan	Neutral	undefined >> undefined	February 24th 2026
NVO	Kepler	Hold	undefined >> undefined	February 24th 2026
NVO	Deutsche Bank	Hold	undefined >> undefined	February 23rd 2026
NVO	Jefferies	Hold	undefined >> undefined	February 12th 2026
NVO	Citigroup	Neutral	undefined >> undefined	January 27th 2026

Press-relizlar

27.03.2026

Articles of Association for Novo Nordisk A/S 2026

500 - Internal server error. Server Error 500 - Internal server error.

Novo Nordisk A/S (NVO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Novo Nordisk A/S (NVO)

Novo Nordisk: A Strong Contender in the Pharmaceutical Arena

Novo Nordisk's Awiqli Gets FDA Approval for Type II Diabetes

Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy?

Novo Nordisk: A Comeback Story In The World's Fastest-Growing Drug Market

Articles of Association for Novo Nordisk A/S 2026

US FDA approves Novo's insulin injection for type 2 diabetes

Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes

Videolar

Reytinglar oshishi / pasayishi

Press-relizlar

Articles of Association for Novo Nordisk A/S 2026

Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes

Resolutions from the Annual General Meeting of Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme